Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty?

E Charmandari, C G D Brook, P C Hindmarsh

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is an autosomal recessive condition in which deletions or mutations of the cytochrome P450 21-hydroxylase gene cause glucocorticoid and often mineralocorticoid deficiency. Despite optimal substitution therapy, control of classical CAH is often inadequate at puberty, and the problems encountered relate to hypocortisolism and/or hyperandrogenism. A number of physiological alterations in the endocrine milieu at puberty, which include alterations in the growth hormone/insulin-like growth factor axis, insulin sensitivity, as well as the activity of enzymes participating in cortisol metabolism and adrenal steroidogenesis, may account for the documented hypocortisolism and elevated androgen production, and may explain the difficulty in maintaining adequate adrenocortical suppression in pubertal patients with classical 21-hydroxylase deficiency.

Congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency is an autosomal recessive condition, in which deletions or mutations of the cytochrome P450 21-hydroxylase gene result in glucocorticoid and often mineralocorticoid deficiency. This leads to increased secretion of adrenocorticotrophic hormone (ACTH) by the anterior pituitary, adrenal hyperplasia, and increased production of androgens and steroid precursors for which 21-hydroxylation is not necessary (fig 1). Glucocorticoid substitution is given to suppress the excessive secretion of corticotrophin releasing hormone (CRH) and ACTH by the hypothalamus and anterior pituitary respectively, and to reduce the circulating concentrations of adrenal androgens. Treatment efficacy reflects the adequacy of adrenocortical suppression and is assessed by monitoring annualised growth velocity, the rate of skeletal maturation, and serum concentrations of androgen precursors.

Despite adequate substitution therapy, however, control of classical 21-hydroxylase deficiency is often difficult and patients are at risk for developing in tandem iatrogenic hypercortisolism and/or hyperandrogenism, both of which are responsible for the main problems encountered in their management, such as compromised final height, obesity, hyperinsulinism, hirsutism, polycystic ovarian syndrome, poor fertility, and psychosocial identification problems.

Limitations of current medical therapy include: (1) inability to control hyperandrogenism without employing supraphysiological doses of glucocorticoid and therefore inducing hypercortisolism; (2) hyperresponsiveness of the hyperfunctioned adrenal glands to ACTH following a small ACTH challenge in the event of escape from pituitary suppression; and (3) difficulty in suppressing the anterior pituitary with glucocorticoids, given that glucocorticoid feedback is only one of the mechanisms governing ACTH secretion.

In addition to the above, a number of clinical observations suggest that puberty imposes greater difficulty in achieving and maintaining adrenal suppression despite optimal doses of substitution therapy. This difficulty in maintaining optimal control in pubertal patients with classical CAH has been attributed traditionally to non-adherence to medical therapy as a result of psychosocial factors relating to adolescence. At puberty, children often rebel against authority in an attempt to gain more control and independence over their world, parental supervision over their medical therapy decreases with the expectation that adolescents will assume responsibility for the treatment tasks, and conformity to peers increases, so that adolescents are inclined not to adhere to a treatment regimen in an attempt to become “normal” and to minimise the risk of rejection by their peers. Regardless of age and developmental stage, adherence to medical therapy may also depend on the frequency of drug administration, the intensity of therapy, the side effects of certain medications, the child’s level of optimism, and the support provided by other members of the family.

Non-adherence to medical therapy, however, only explains in part the problems encountered in the management of pubertal patients with classical CAH. There is increasing evidence to suggest that alterations in the endocrine milieu at puberty may influence cortisol pharmacokinetics and, consequently, the handling of hydrocortisone used as replacement therapy. Recent studies have...
shown a significant increase in cortisol clearance at puberty (fig 2A), and a shorter half life of free cortisol in pubertal females compared to their male counterparts (fig 2B).

Puberty results from increased gonadotrophin secretion from the anterior pituitary in response to gonadotrophin releasing hormone (GnRH) secretion from the hypothalamus. The rise in sex steroid concentration is associated with increased growth hormone (GH) secretion from the anterior pituitary, which leads to increased insulin-like growth factor (IGF)-I concentrations and the pubertal growth spurt.

Associated with this there is a decrease in insulin sensitivity and a parallel elevation in insulin concentrations. At the tissue level, insulin reduces IGF binding protein 1 (IGFBP-1) concentrations, altering tissue exposure to IGF-I.

The increase in cortisol clearance at puberty is primarily the result of inhibition of the activity of 11β-hydroxysteroid dehydrogenase type I (11β-HSD1) secondary to the alterations in the endocrine milieu. 11β-HSD1 is one of the main hepatic enzymes participating in cortisol metabolism, which acts predominantly as an oxo-reductase, converting inactive cortisone to active cortisol. The increase in GH, IGF-I, and oestriol concentrations at puberty can have an independent or a combined effect in causing a decrease in the activity of 11β-HSD1. The effect of IGF-I on 11β-HSD1 activity is further enhanced by the decrease in IGFBP-1 concentrations secondary to the raised insulin concentrations. Inhibition of 11β-HSD1 activity effectively increases the metabolic clearance rate of cortisol. An additional mechanism that results in increased cortisol clearance is the increase in renal clearance of cortisol secondary to an increase in glomerular filtration rate (GFR) in response to the raised GH and IGF-I concentrations. IGF-I increases GFR via a direct effect on the glomerular vasculature and a decrease in renal glomerular afferent and efferent arteriolar resistance, while the action of GH is likely to be mediated by IGF-I.

The above changes in cortisol pharmacokinetics, if the administration schedule of oral hydrocortisone remains unchanged, will result in hypocortisolism, loss of control of the hypothalamic–pituitary–adrenal (HPA) axis, inadequate suppression of the adrenal cortex, and excessive production of androgens and steroid precursors. The increased secretion of adrenal androgens will be further amplified by the increased 17, 20 lyase activity and/or decreased 3β-hydroxysteroid dehydrogenase (3β-HSD) activity secondary to the rise in GH, IGF-I, IGF-II, and insulin concentrations at puberty. Moreover, the increased insulin concentrations will suppress the synthesis of sex hormone binding globulin by the liver, further enhancing hyperandrogenism.

As androgens and androgen precursors are known to compete with exogenously administered glucocorticoids for the same receptors, both hypocortisolism and hyperandrogenism will operate as independent factors to amplify the loss of control. Increased ACTH...
secretion, in turn, may further potentiate hypocortisolism by increasing the metabolic clearance rate of cortisol.15

Besides the above alterations in cortisol pharmacokinetics at puberty, obesity is an important factor that contributes significantly to the problems encountered in the management of these patients. Children with classical 21-hydroxylase deficiency have significantly higher values of body mass index (BMI) and fat mass throughout childhood compared to their normal counterparts.14 This most likely reflects the supraphysiological doses of glucocorticoid often employed in an attempt to suppress the adrenal cortex effectively, and/or the impaired adrenomedullary function and decreased catecholamine secretion documented in these patients.15 Compared to normal subjects matched for age and BMI, children with classical CAH also have significantly higher serum insulin concentrations and insulin resistance index, as determined by the homoeostasis model assessment method.16 This is probably the result of long standing adrenocortical hypofunction in association with intermittent hypocortisolism and/or adrenal hyperandrogenism. Hyperinsulinaemia and insulin resistance, in turn, may further stimulate adrenal and ovarian steroidogenesis, and may play an important role in the development of polycystic ovary syndrome,17 metabolic syndrome related atherosclerotic cardiovascular disease in adults,18,19 and adrenal incidentalomas.20-23 Recent studies have shown that the half life of free cortisol is significantly shorter in pubertal females with classical CAH compared to their male counterparts.24 These observations may explain why management of female patients at puberty is often problematic, and indicate more frequent administration of oral hydrocortisone in these patients.

We conclude that in children with classical 21-hydroxylase deficiency, alterations in the endocrine milieu at puberty may result in inadequate suppression of the HPA axis despite optimal substitution therapy and adherence to treatment. The increase in GH secretion and the rise in IGF-1 and oestriadiol concentrations result in decreased conversion of cortisone to cortisol, and hypocortisolism. In addition, these alterations in association with the raised insulin concentrations at puberty lead to increased adrenal and ovarian androgen production. Both hypocortisolism and hyperandrogenism result in increased ACTH secretion, which, in turn, may further potentiate hypocortisolism by increasing the metabolic clearance rate of cortisol, thus establishing a vicious cycle. Administration of oral hydrocortisone should be more frequent than twice daily in pubertal patients with classical CAH, particularly in females.

**Authors’ affiliations**

E Charmandari, C G D Brook, P C Hindmarsh, London Centre for Paediatric Endocrinology, University College London, London, UK

**REFERENCES**

Classical congenital adrenal hyperplasia at puberty


Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty?

E Charmandari, C G D Brook and P C Hindmarsh

Arch Dis Child 2002 86: 266-269
doi: 10.1136/adc.86.4.266

Updated information and services can be found at:
http://adc.bmj.com/content/86/4/266

These include:

References
This article cites 43 articles, 10 of which you can access for free at:
http://adc.bmj.com/content/86/4/266#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Adrenal disorders (45)
- Sexual health (352)
- Reproductive medicine (945)
- Drugs: endocrine system (120)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/